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g/10.1016Abstract Behc¸et’s disease (BD) is a systemic vasculitis which is characterised by oral, aphthous
ulcers, genital ulcers, skin lesions and ocular manifestations. Although the aetiopathogenesis of
BD is still unknown, the critical role of Th1 immune responses, neutrophil hyperactivation along-
side overproduction of pro-inﬂammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-8, tumour
necrosis factor-alpha (TNFa) and particularly IL-17 have been demonstrated in the immunopatho-
genesis of the disease. Despite signiﬁcant progress in understanding of the aetiology of the disease,
its treatment remains intricate, and is still treated with immune-suppressive drugs and biological
agents with probable systemic side effects. Accordingly, there is a necessity to establish the more
efﬁcient and less toxic therapeutic methods which may offer a long-time remission of BD.
Mesenchymal stem cells (MSCs) are non-haematopoietic and multipotential stem cells with
immunosuppressive capacities in innate and acquired immune systems. MSCs can migrate to dam-
aged tissues and prevent secretion of proinﬂammatory cytokines and other immunomodulatory
effectors, increasing the survival of damaged cells, although the exact underlying mechanisms are
still unknown. For this purpose, numerous herpes simplex viruses are injected into C57BL/6 mice
to produce Behc¸et’s mouse model and transferring a certain number of MSCs may have therapeutic, T lymphocyte helper 1; Treg, T regulatory; IL, interleukin; TNF-a, tumour necrosis factor alpha; IFN-c,
th factor beta; NK, natural killer cell; HLA, human leucocyte antigen; MHC, major histocompatibility
MSCs, mesenchymal stem cells; pfu, plaque-forming unit; DMEM, Dulbecco’s modiﬁed Eagle’s medium;
of differentiation; Sca-1, stem cell antigen-1; Vcam-1, vimentin cell adhesion molecule-1; HSV, herpes
saline; IHC, i; RT-PCR, reverse transcriptase–PCR.
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24 T. Mazaheri et al.value for control of Behc¸et’s animal model, so researchers could deliberate the function of MSCs
and proinﬂammatory cytokines particularly IL-17A-F, TNF-a, interferon gamma (IFN-c), IL-2,
IL-6 and IL-8 in an experimental model.
The aim of this hypothesis is to evaluate immunosuppressive and immunomodulatory properties
of MSCs in syngeneic animal model for BD, in order to clarify the mechanisms of MSCs in BD
management, as a broad and more conﬁdent treatment in clinical application.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license. Introduction
Behc¸et’s disease (BD) is an immune-mediated, chronic and
relapsing disorder which is currently thought to be an autoim-
mune/autoinﬂammatory syndrome [1,2]. This multisystem dis-
ease is mostly common among young men and women in the
Far East, Mediterranean countries and Middle East including
Iran [3]. BD is characterised by oral aphthosis, genital ulcers,
skin lesions and ocular manifestations. Vascular, cardiopulmo-
nary and neurological involvements are some minor manifesta-
tions of the disease which are rare but important because they
could have irreversible complications [3,4].
The exact details about the aetiopathogenesis of BD are still
unknown, although it has been well established that a combina-
tion of genetic predisposition, (the most described gene in this
regard is human leucocyte antigen-B51 (HLA-B51) [5], environ-
mental factors and infectious agents could lead to disturbances
in immune responses and thereby participate in the pathogenesis
of BD [6,7]. Dysfunction of hypothalamo–pituitary–adrenal
axis,modiﬁed levels of prolactin, sex hormones and some neuro-
peptides withmain biological effect on both innate and acquired
immune system are also associated with long-term stress in BD
[4]. The immunopathogenesis is shown in Fig. 1. Initially, inter-
nal antigens such as organ-speciﬁc proteins and external anti-
gens such as viruses and micro-organisms encounter the T
cells (ab-T cells and dc-T cells) through antigen-presenting cells
(APCs) which leads to lymphocyte activation.Hyperactivated T
lymphocyte helper 1 (Th1) produces proinﬂammatory cytokines
such as interleukin 2 (IL-2), IL-6, IL-8, IL-17, tumour necrosis
factor alpha (TNF-a) and interferon gamma (IFN-c). These
cytokines stimulate neutrophils and activate monocytes. Acti-
vated monocytes promote Th1 differentiation via release of
IL-12 and hyperfunction of neutrophils causes tissue injury.
As a whole, association between APCs, hypersensitivity of T
lymphocytes and hyperactivity of neutrophils could be the main
reason for immune responses in BD [4,7–9].
In addition to the considerable impression of Th1 and Th2,
recent studies illustrate that IL-17 has a consequential and
exclusive role in BD pathogenesis [10,11]. IL-17 mainly pro-
duces a high value of IL-22, IL-17A-F and TNF-a. As reported
in previous studies, IL-23, IL-6 and tumour growth factor beta
(TGF-b) trigger Th-1 differentiation from naive T cells. Addi-
tionally, IL-21, which is the major increased cytokine in active
phase, involved in Th17/(regulatory T lymphocyte) Treg equi-
librium regulating and decreased Treg cell frequency [12].
Additionally, humoral immunity system is also involvedwith
a minor role, in the pathogenesis of BD. Enhancing of autoan-
tibodies such as cardiolipin and immune complexes (antigen–
antibody complex) has been reported in more than half of pa-
tients with BD, speciﬁcally in the active phase of the disease
[8] which probably is associated with severity of the disease [13].BD is treated with immunosuppressant drugs and biologi-
cal agents such as monoclonal antibodies which are associated
with severe systemic side effects [14,15]. Unfortunately, there
are still cases of severe and life-threatening BD, refractory to
conventional medications and biological agents [3]. Less toxic
and more effective therapeutic options are needed for BD pa-
tients, especially with devastating complications.
Non-haematopoietic MSCs are precursor multipotential
cells which are being obtained from many tissues, particularly
bone marrow. In addition to the capacity of differentiation
into mesodermal cell line, these cells can operate as modulators
of immune system [16]. MSCs have the ability to inhibit T lym-
phocyte cell cluster of differentiation (CD4 and CD8), activa-
tion and proliferation [17,18].
Furthermore, MSCs reduce secretion of IL-2, IL-12, INF-c
and TNF-a and induce production of IL-4 and IL-10. Recent
studies have demonstrated that MCSs probably have this po-
tency to secrete cytokines, hence could switch equivalence be-
tween Th2/Th1 towards Th2 [19–21]. In fact, MSCs, on the one
hand, could repress development of proinﬂammatory Th1 and
natural killer cell (NK) signals and, on the other hand, expand
the range of anti-inﬂammatory Th2 and T repressor cells [22].
Recent studies exhibited that MSCs inhibit TH17 differen-
tiation from naive T cells [23]. MSCs can also decrease the
expression of major histocompatibility complex class E
(MHC class E) [24].
Generally, in vivo and in vitro immunosuppressive effect of
MSCs have been demonstrated for autoimmune diseases such
as diabetes [25], lupus erythematosus [26], rheumatoid arthritis
[27,28] and autoimmune encephalomyelitis [29] with an effec-
tive role in treatment of animal models. Furthermore, trans-
plantation of MSCs in patients with autoimmune disorders,
such as multiple sclerosis [30], scleroderma [31] and systemic
lupus erythematosus [32], has encouraging results.
Although the use of MSCs has been established as a non-
toxic, available therapeutic procedure with poor immunogenic-
ity [33], there are, nevertheless, many ambiguities in this area.
Despite frequent efforts, the exact mechanisms underlying
immunomodulatory effects of MSCs for its therapeutic appli-
cation remain unclear [34]. Certainly, more studies are neces-
sary to determine the immunosuppressive mechanisms of
MSCs for broad application in treatment of patients.
In this article, we proposed that MSCs could have an impor-
tant role in inhibiting cytokines such as IL-17, INF-c and TNF-
a genes via post-transcriptional and post-translational regula-
tions of gene expression in Behc¸et’s experimental model.
The hypotheses
Clinicians still face severe and life-threatening cases of BD
resistant to conventional immune-suppressive medications
Figure 1 Immunomodulatory property of MSCs and BD immunopathogenesis.
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humoral immunity in pathogenesis of BD, we hypothesize that
usage of immune-modifying properties of MSCs could be more
efﬁcient and competent in the control of induced BD in animal
model. The use of MSCs in clinical application is associated
with special restrictions, because the exact underlying mecha-
nisms are not well established. The aim of this hypothesis is
to evaluate MSCs’ molecular and cellular mechanisms, in-
volved in BD control, in an experimental model. It is obvious
that the more investigators study about MSCs’ underlying
mechanisms, the affected individuals will be treated with the
more efﬁcacy and reliability.Evaluation of hypotheses
We suggest a syngeneic model of BD to evaluate the immuno-
modulatory effects of non-haematopoietic MSCs in control or
full recovery of disease by improving clinical symptoms,behavioural changes of models and investigating the role of
MSCs in inhibiting cytokines such as IFN-c, TNF-a and IL-
17 genes via post-transcriptional and post-translational regula-
tions of gene expression in Behcet’s syngeneic animal model.
Research design and methods
1. Injection of 1.0 · 106 plaque forming units (pfu ml–1) her-
pes simplex virus type 1 (KOS strain) to earlobes of 20
C57BL/6 mice (considering that C57BL/6 is the only
instance in Iran); after 4 weeks the second injection is
administered to produce Behc¸et’s mouse model according
to the Hirata et al. method [35]. As controls 10 mice are
inoculated in the same site with culture medium. The
induced BD-like major symptoms are included, eye syn-
drome, genital, oral and other skin ulcers. Gastrointestinal
ulcers, arthritis and neurological involvement are deﬁned as
minor symptoms (two or more symptoms in mice are con-
sidered as a BD-like syndrome) [36].
26 T. Mazaheri et al.2. Isolation of MSCs from 6–8-week-old C57BL/6 mice.
C57BL/6 mice are euthanised by cervical dislocation. Bone
marrow is collected from tibia and femur of mice. 70 · 106
bone marrow cells from one donor are obtained [37,38].
Then 25 · 106 cells are prepared [38] and suspended in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) containing
15% foetal bovine serum (FBS), penicillin and streptomy-
cin. After 24 h, cells are washed and non-adherent cells,
which mostly are haematopoietic stem cells, removed.
Adherent cells are cultured in complete medium for 1 week
until they covered 80–90% of the bottom of the culture bot-
tle. MSCs from passages 4 are used in the subsequent
experiments. Mature MSCs are determined by their ability
to differentiate into adipocytes and osteocytes. Further
properties are based on the expression of surface markers
such as CD34. CD44, stem cell antigen-1 (Sca-1) and
vimentin cell adhesion molecule-1 (Vcam-1) [37,38].
3. Transferring 5 · 106 syngeneic MSCs (isolated from
C57BL/6 mice) to both BD-induced models [33], and the
affected group with herpes simplex virus (HSV-1), without
any clinical manifestations, to study the therapeutic effects
of MSCs. An equal volume of phosphate-buffered saline
(PBS) is used in the control group [33].
4. Comparing clinical manifestations of MSCs treated with
the control group and evaluating probable cellular and
molecular mechanisms of MSCs, which is shown in
Fig. 1, by means of RT-PCR, ﬂow cytometry and immuno-
histochemistry (IHC) in models.
5. All assessments were conducted in four separate groups: (1)
Control: normal mice C57BL/6. (2) Control model group,
without MSC transplantation (BD is induced in these
mice). (3) BD-induced mice model that have received the
MSCs which is divided into three categories: (1) MSCs will
be inoculated into mouse models before injection of HSV-1
in the ﬁrst group. (2) In the second group, MSCs will be
inoculated simultaneously with HSV-1 into animal models.
(3) Eventually, in the third group, MSCs will be transferred
after HSV-1 induction, when clinical manifestations have
been stabilised in models. (4) The fourth group containing
mice did not show any clinical symptoms, despite inocula-
tion of HSV-1. This group is also treated with MSCs.
The fourth group of this experiment probably will be
advantageous, because different individuals are exposed
to variable environmental factors such as viruses.Conclusion and discussion
Nowadays, it has been established that MSCs have the poten-
tial of suppressing the immune response via inhibiting the mat-
uration of dendritic cells and suppressing the function of T
lymphocytes, B lymphocytes and NK cells. A proper animal
model of BD can be useful to evaluate the immune suppressor
effects of MSCs in control or full recovery of disease by
improving clinical symptoms, behavioural changes of model
and investigating probable cellular and molecular mechanisms
of MSCs such as TNFa and IFN- c and IL-17 gene expression.
The use of of animal model helps to clarify the cellular and
molecular principles involved in BD pathogenesis and exacer-
bation of inﬂammation, and also provides the possibility of
creating novel drugs, for preventive, controlling and therapeu-
tic objects, with less toxicity and side effects. In cell therapy,immunologic responses in recipients are detected as a major
obstacle, which is eliminated with the use of syngeneic system.
Achievement of these mechanisms in the future, in addition to
the use of MSCs as a cell therapy strategy, could lead to trans-
fected MSCs as a vector, in order to candidate gene delivery
for disease management.
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First Question: What do we already know about the
subject?
BD is still associated with devastating complications
despite current treatments. Critical role of cellular and hu-
moral immunity is proved in the pathogenesis of the dis-
ease. The immune-modulator functions of MSCs have
been described.
Second Question: What does your proposed theory add to
the current knowledge available, and what beneﬁts does it
have?
We hypothesised that, using immunomodulatory proper-
ties of MSCs in disease control in an experimental model
of BD, and also evaluating its appropriate cellular and
molecular mechanisms could be effective for BD patients
not responding to common treatments.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
We induce Behc¸et’s animal model with injection of HSV-1
in C57BL/6 mice and transmission of MSCs into synge-
neic mouse model, to evaluate the effects of MSCs in clin-
ical symptom improvement and identiﬁcation of its
cellular and molecular mechanisms compared to the
controls.Acknowledgement
We would like to express our gratitude to honourable profes-
sor Dr. A.R. Esmaeilzadeh, who taught us to think and
encouraged students to present innovative hypothesis.References
[1] McGonagle D, McDermott MF. A proposed classiﬁcation of
the immunological diseases. PLoS Med 2006;3:e297.
[2] Direskeneli H. Autoimmunity vs autoinﬂammation in Behcet’s
disease: do we oversimplify a complex disorder? Rheumatol
(Oxford) 2006;45:1461–5.
[3] Davatchi F, Shahram F, Chams-Davatchi Ch, Shams H, Nadji
A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F.
Behcet’s disease: from east to west. Clin Rheumatol
2010;29:823–33.
[4] Tursen U. Pathophysiology of the Behcet’s disease. Patholog
Res Int 2012;493015.
Introducing the immunomodulatory effects 27[5] Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A,
Aizawa M. Close association of HLA-Bw51 with Behcet’s
disease. Arch Ophthalmol 1982;10:1455–8.
[6] Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N
Engl J Med 1999;341:1284–91.
[7] Kapsimali V, Kanakis M, Vaiopoulos G, Kaklamanis PH.
Etiopathogenesis of Behc¸et’sdisease with emphasis on the role of
immunological aberrations. Clin Rheumatol 2010;29:1211–6.
[8] Tursen U. Activation markers in Behcet’s disease. Turkderm
2009;43:74–86.
[9] Hirohata SH, Kikushi H. Behcet disease. Arthritis Res Ther
2003;5:139–46.
[10] Akdis CA, Akdis M. Mechanisms of allergen-speciﬁc
immunotherapy. J Allergy Clin Immunol 2011;127:18–27.
[11] Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez
E, et al.. Interleukins, from 1 to 37, and interferon-gamma:
receptors, functions, and roles in diseases. J Allergy Clin
Immunol 2011;127(701–721):e1–e70.
[12] Geri G, Terrier B, Rosenzwajk M, Wechsler B, Touzot M,
Seilhean D, et al.. Criticalrole of IL-21 in modulating Th17 and
regulatory T cells in Behcet disease. J Allergy Clin Immunol
2011;128:655–64.
[13] Musabak U, Baylan O, Cetin T, Yesilova Z, Sengul A, Saglam
K, et al.. Lipid proﬁle and anticardiolipin antibodies in Behc¸et’s
disease. Arch Med Res 2005;36:387–92.
[14] Alpsoy E, Akman A. Behc¸et’s disease: an algorithmic approach
to its treatment. Arch Dermatol Res 2009;301:693–702.
[15] Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H,
Mochizuki M, et al.. Efﬁcacy, safety, and pharmacokinetics of
multiple administration of inﬂiximab in Behc¸et’s disease with
refractory uveoretinitis. J Rheumatol 2004;31(7):1362–8.
[16] Djouad F, Boufﬁ C, Ghannam S, Danie`le Noe¨l D, Jorgensen C.
Mesenchymal stem cells: innovative therapeutic tools for
rheumatic diseases. Nat Rev Rheumatol 2009;5:392–9.
[17] Glennie S, Soeiro I, Dyson PJ, Lam EWF, Dazzi F. Bone
marrow mesenchymal stem cells induce division arrest anergy of
activated T cells. Blood 2005;105:2821–7.
[18] Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F,
Pistoia V, et al.. Human mesenchymal stem cells promote
survival of T cells in a quiescent state. Stem Cells 2007;25:
1753–60.
[19] Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D. Mesenchymal stem
cells might be used to induce tolerance in heart transplantation.
Med Hypotheses 2008;70:785–7.
[20] Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD,
Dickinson AM, et al.. Adult human ﬁbroblasts are potent
immunoregulatory cells and functionally equivalent to
mesenchymal stem cells. J Immunol 2007;179:1595–604.
[21] Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni
PD, Matteucci P, et al.. Human bone marrow stromal cells
suppress T-lymphocyte proliferation induced by cellular or
nonspeciﬁc mitogenic stimuli. Blood 2002;99:3838–43.
[22] Carrio´n F, Nova E, Luz P, Apablaza F, Figueroa F. Opposing
effect of mesenchymal stem cells on Th1 and Th17 cell
polarization according to the state of CD4+ T cell activation.
Immunol Lett 2011;135:10–6.
[23] Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H.
Mesenchymal stem cells inhibit human Th17 cell differentiation
and function and induce a T Regulatory cell phenotype. J
Immunol 2010;185:302–12.[24] Aggarwal S, Pittenger MF. Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood 2005;105:
1815–8.
[25] Urban VS, Kiss J, Kovacs J, Yamaza T, Hou Y, Zhao S, et al..
Mesenchymalstem cells cooperate with bone marrow cells in
therapy of diabetes. Stem Cells 2008;26:244–53.
[26] Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al..
Mesenchymal stem cell transplantation reverses multiorgan
dysfunction in systemic lupus erythematosus mice and
humans. Stem Cells 2009;27:1421–32.
[27] Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell
therapy using allogeneic bone marrow mesenchymal stem
cellsprevents tissue damagein collagen-induced arthritis.
Arthritis Rheum 2007;56:1175–86.
[28] Mao F, Xu WR, Qian H, Wei Zhu W, Yan YM, Shao QX,
et al.. Immunosuppressive effects of mesenchymal stem cells
in collagen-induced mouse arthritis. Inﬂamm Res 2010;59:
219–25.
[29] Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M,
Williams P, Birman E, et al.. Mesenchymal stromal cells
ameliorate experimental autoimmune encephalomyelitis by
inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-
dependent manner. J Immunol 2009;182:5994–6000.
[30] Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F,
Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP,
Lee RR, Minev B. Nonexpanded adipose stromal vascular
fraction cell therapy for multiple sclerosis. J Transl Med
2009;7:29.
[31] Christopeit M, Schendel M, Fo¨ll J, Mu¨ller LP, Keysser G, Behre
G. Marked improvement of severe progressive systemic sclerosis
after transplantation of mesenchymal stem cells from an
allogeneic haploidentical-related donor mediated by ligation of
CD137L. Leukemia 2008;22:1062–4.
[32] Sun L, Liang J, Zhang H, Jiao C, Zhang L, Zhao S, et al..
Allogenic mesenchymal stem cells transplantation in refractory
systemic lupus erythematosus: a pilot clinical study. Ann Rheum
Dis 2010;69:1423–9.
[33] Zhang X, Ren X, Li G, et al.. Mesenchymal stem cells
ameliorate experimental autoimmune uveoretinitis by
comprehensive modulation of systemic autoimmunity. Invest
Ophthalmol Vis Sci 2011;52:3142–52.
[34] Herrero C, Pe´rez-Simo´n JA. Immunomodulatory effect of
mesenchymal stem cells. Braz J Med Biol Res 2010;43:
425–30.
[35] Hirata Y, Sugita T, Gyo K, Yanagihara N. Experimental
vestibular neuritis induced by herpes simplex virus. Acta
Otolaryngol Suppl (Stockh) 1993;3:79–81.
[36] Sohn S, Lee E, Lee S. The correlation of MHC haplotype and
development of Behcet’s disease-like symptoms induced by
herpes simplex virus in several inbred mouse strains. J Dermatol
Sci 2001;26:173–81.
[37] Soleimani M, Nadri S. A protocol for isolation and culture of
mesenchymal stem cells from mouse bone marrow. Nat
Protocols 2009;4:102–6.
[38] Nadri S, Soleimani M. Isolation of CD34+ mesenchymal stem
cells from mouse bone marrow. SJIBTO 2007;4:143–51.
